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Abstract: Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. 
Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear 
cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine 
kinase inhibitors (TKIs), which have become the standard of care in managing advanced clear 
cell RCC. Among the newest of these agents to receive Food and Drug Administration approval 
in this disease is pazopanib. This review will summarize what is known about the fundamental 
biology that underlies clear cell RCC, the data surrounding the previously approved targeted 
agents for this disease, including not only the TKIs but also the mTOR inhibitors and the vascular 
endothelial growth factor-specific agent, bevacizumab, and the newest TKI, pazopanib. It will 
also explore the potential role for pazopanib relative to the other available agents and where it 
may fit into the armamentarium for treatment of advanced/metastatic RCC.
Keywords: pazopanib, targeted therapy, tyrosine kinase inhibitor, clear cell renal cell 
carcinoma
Introduction
With 57,760 newly diagnosed cases anticipated for 2009 and an estimated 12,980 
deaths from renal cell carcinoma (RCC), this disease remains a significant public 
health issue.1 It is known that the incidence of RCC is steadily rising, but the reasons 
underlying this observation remain unknown.2 For those who present with clinically 
localized tumors, surgery remains the mainstay of therapy and will cure the majority 
of patients. However, at least one-third of patients will either present with advanced 
or metastatic disease or develop this after initial curative resection.3 For this group of 
patients the prognosis is considerably worse. It is now well established that RCC is 
relatively resistant to traditional cytotoxic chemotherapy. Therefore, for many years 
the mainstay of therapy was based on cytokine-mediated approaches using either 
interferon alpha (IFNα) and/or interleukin-2 (IL-2). The results with these agents were 
less than satisfactory because they produced objective response rates in the order of 
only 10%–20%, with long-term durable responses in less than 5% of cases, at least 
for high-dose IL-2.4,5 Within the last 5 years there have been substantial gains in the 
management of advanced RCC that offer both hope and a new set of challenges and 
questions. The mainstay of these approaches is grounded in a deeper understand-
ing of the biology of RCC and the so-called “targeted therapies” designed to attack 
specific important aspects RCC pathobiology. Several basic approaches have been 
utilized, including a class of agents designed to block the action of tyrosine kinase. Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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The tyrosine kinase inhibitors (TKIs) can often block the 
activity of more than one kinase, including those that act as 
receptors for important ligands in RCC biology, including 
vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF). This review will focus on the 
published results of one of these new targeted therapies for 
RCC, the second-generation TKI, pazopanib. The aim will 
be to review the biology pertinent to RCC and the targeted 
therapies, summarize the other agents in this general class, 
describe the data specific to pazopanib, and to explore where 
pazopanib fits in the global approach to advanced RCC, and 
what questions remain to be answered.
Clear cell renal cell carcinoma: 
central role of VHL
There are at least 5 histologic forms of RCC, but by far 
the most prevalent is the clear cell (or conventional) type 
(ccRCC), which accounts for 75% of cases.6 The second most 
common is papillary RCC, which has two subtypes (Type 1 
and Type 2), both of which have biology distinct from ccRCC. 
Type 1 papillary RCC is believed to be due to aberrations 
of the c-Met proto-oncogene, while Type 2 papillary RCC is 
thought to be due to mutations or abnormalities of the gene 
for fumarate hydratase, an enzyme involved in the Krebs 
cycle.7 At this time there are no specific agents available to 
target these distinct pathways outside the context of a clini-
cal trial, so this review focuses specifically on the molecular 
biology of ccRCC. The pathogenesis of ccRCC centers on 
aberrations in the von Hippel-Lindau (VHL) gene and its 
protein product. Under normal conditions, the VHL protein 
predominantly functions in the oxygen sensing machinery 
of the cell and the cellular response to hypoxia.8–13 VHL 
complexes with several other proteins in the cytoplasm of 
the cell, specifically elongin B, elongin C, cullin-2, and Rbx, 
as part of an E3 ligase complex.14–20 This   regulatory complex 
operates by ubiquitinating proteins, thereby   marking them 
for subsequent degradation by the proteosomal   machinery 
of the cell.21,22 Under normoxic conditions, a critical regu-
latory molecule, known as hypoxia-inducible factor alpha 
(HIFα), is hydroxylated by a series of oxygen-sensitive 
prolyl-hydroxylases. Hydroxylation of these proline residues 
allows the E3 ligase complex to bind HIFα, predominantly 
through the protein VHL.23,24 The binding of VHL and 
the E3 ligase complex to HIFα leads to the latter being 
  ubiquitinated and marked for subsequent degradation.25–30 
As a result, in the typical cellular environment, in which 
there are normal oxygen levels, the amount of HIFα within 
the cell is maintained at a low level.
In contrast, under hypoxic conditions, HIFα is not 
hydroxylated, and therefore fails to bind to VHL and the E3 
ligase complex, so is not degraded (see Figure 1). The nor-
mal cellular response to hypoxia is therefore to raise HIFα 
  levels, allowing it to build up within the cytoplasm and bind 
with a similar molecule, HIFβ. This HIFα/β heterocomplex 
then translocates to the nucleus and binds regions of nuclear 
DNA known as hypoxia response elements (HRE) within 
the promoters of genes important in the cellular response 
to hypoxia. Binding of the HIFα/β complex to HRE in 
the promoter region, in turn, transcriptionally upregulates 
mRNA and subsequent protein levels. The critical HIFα-
regulated genes include VEGF, PDGF, transforming growth 
  factor alpha (TGFα), carbonic anhydrase IX, erythropoietin, 
  glucose transporter, and others.
When there is an abnormality or mutation in the VHL 
protein such that it either cannot function or its levels are 
abnormally low or absent in the cell, HIFα cannot be bound 
to the E3 ligase irrespective of the oxygen levels in the cell, 
and so is constitutively present at high levels (see Figure 1). 
Constitutively high cellular levels of HIFα in turn lead to 
ongoing interaction of HIFα/β complexes with HRE in the 
nucleus and the genes normally regulated by HIF, such as 
VEGF, PDGF, and TGFα, will be abnormally activated, lead-
ing to the development of ccRCC.
Vascular endothelial growth  
factor and its receptor
Although HIFα regulates a number of genes, the one which 
has been the focus of most research and drug develop-
ment has been that for VEGF which plays a central role in 
angiogenesis, ie, the process of making new blood vessels, 
including those generated by tumors as they grow. It is now 
recognized that this process of tumor-induced   angiogenesis 
is critical to malignant tumor progression across a variety 
of tumors. Clinically it has also been long appreciated that 
ccRCCs in particular are generally hypervascular tumors.31–33 
The family of VEGF proteins includes several subtypes, ie, 
VEGF-A, -B, -C, -D, -E, and placenta growth   factor-1.34–37 
These protein ligands in turn exert their action by binding to 
one or more receptors specific for VEGF at the cell surface, 
VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 
(Flt-4).34–37 Among these receptors, it is generally felt that 
VEGFR-1 and -2 are more important for angiogenesis, 
whereas VEGFR-3 is more important for lymphangio-
genesis.37 Pazopanib was initially discovered as part of a 
drug screen for molecules that would block the action of 
VEGFR-2.38,39Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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All members of the VEGF receptor family are cell 
  membrane-associated tyrosine kinases. When VEGF (the 
ligand) binds to its receptor (VEGFR), it induces a conforma-
tional change in the receptor that switches on its tyrosine kinase 
activity. This kinase activity phosphorylates key proteins in a 
series of signaling cascades that include a series of molecules 
that are often also tyrosine kinases themselves. Examples of 
these signaling cascades include the RAF-MEK-ERK series 
of kinases and the phosphatidylinositol-3 kinase-AKT-mTOR 
pathway. The activation of these pathways in turn is what 
leads to changes in endothelial cell activation, proliferation, 
migration, and cell survival.34–37,40 This complex interplay 
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Figure 1 Biology of the von Hippel-Lindau/hypoxia-inducible factor (VHL-HIF) axis in the setting of hypoxia or a mutation or aberration of the VHL gene product. In normoxic 
conditions, HIFα is hydroxylated on specific proline residues by prolyl-hydroxylases. VHL acts as the sensor for these hydroxylated proline residues as part of the VHL-E3 
ubiquitin ligase. This polyubiquitinates HIFα and marks it for degradation by the proteasome. In hypoxic conditions (or in the presence of aberrant VHL), HIFα is allowed 
to accumulate in the cell. It associates with HIFβ and this complex translocates to the nucleus and acts as a transcription factor binding to hypoxia response elements and 
upregulating oxygen-sensitive genes. These HIF-responsive genes include vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming 
growth factor alpha (TGFα), glucose transporter-1 (GLUT1), carbonic anhydrase IX (CA-IX), erythropoietin (EPO), and others. Examples of selected receptors are given, 
including VEGF receptor (VEGFR), PDGF receptor (PDGFR), and the receptor for TNFα and epidermal growth factor receptor (EGFR). Shown is the downstream signaling 
for one of these receptors, VEGFR, including through the PI3 kinase (PI3K)/AKT/mTOR, p38 MAP kinase (p38MAPK), and RAS/RAF/MEK/ERK pathways. Examples of agents 
(including pazopanib) that impact on this cascade are given, and where they act on the pathway is shown.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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between multiple pathways, including those from other HIF 
target genes, ultimately leads to carcinogenesis through a 
mechanism that has not been completely elucidated to this 
point.
The key therapeutic observations from this biology are 
that kinases are critical components at several levels in this 
process, so an agent such as pazopanib or the other TKIs, 
that are able to block tyrosine kinase activity may be able 
to inhibit this cascade at several levels, depending on the 
kinase specificity of the particular agent. Another important 
  observation with therapeutic implications is that the mam-
malian target of rapamycin (mTOR), a potential downstream 
target of VEGF, also acts to increase the starting cellular lev-
els of HIFα.41 Therefore, in theory, abnormal VHL function 
can set up a vicious cycle in which HIFα levels rise, leading 
to abnormally high VEGF levels, which bind to and abnor-
mally increase VEGFR activity, which leads to abnormally 
high activation of the phosphatidylinositol-3 kinase-AKT 
  pathway. While this has many potential downstream effects, 
one is to activate mTOR. This can then induce even higher 
levels of HIFα. In principle, this could lead to a vicious 
positive feedback loop exacerbating the defect started by 
abnormal VHL function.
VHL-HIF-VEGF biology 
and targeted therapy
Understanding the basic biology underlying ccRCC, in 
  particular the central role played by the VHL-HIF-VEGF 
axis, is important because the various members of this cascade 
are the therapeutic targets for most of the agents currently 
used in the management of advanced ccRCC. The concept of 
targeting these specific signaling molecules is the fundamental 
underpinning of the so-called “targeted therapies”, which 
are now the standard of care in managing this disease. This 
principle has resulted in two fundamental, but interrelated, 
categories of targeted therapeutics, ie, those that block the 
mTOR pathway and those that block the VEGF pathway.
Inhibitors of the mTOR pathway
As already described, aberrations in VHL underlie 
  carcinogenesis in ccRCC predominantly through the accu-
mulation of HIFα. Therefore, one potential way to target 
ccRCC is to block those pathways which regulate the starting 
levels of HIFα. Of the many potential pathways that influ-
ence HIF expression, from a therapeutic standpoint the most 
important is the Akt/mTOR pathway. Due to the vicious 
positive feedback loop discussed previously, a number of 
agents that inhibit mTOR have been developed (rapamycin, 
  temsirolimus, and everolimus).41–43 Of these, only temsiroli-
mus and everolimus have Level 1 evidence supporting their 
use and are approved by the Food and Drug Administration 
(FDA) for the management of advanced RCC.
Temsirolimus is a water-soluble ester of sirolimus, 
an older agent. In a large-scale, prospective, randomized 
Phase III trial in which patients with high-risk metastatic RCC 
were randomized to receive intravenous temsirolimus alone, 
IFNα alone, or both agents, temsirolimus as monotherapy 
improved both progression-free survival and overall s urvival 
compared with either IFNα or the combination.44 As a result 
of this study, temsirolimus is generally the preferred front-line 
option in patients with high-risk metastatic ccRCC. It is also 
worth noting that in the Phase III temsirolimus trial, some 
patients with non-ccRCC were included in the study and tem-
sirolimus showed activity in these patients as well. Therefore, 
temsirolimus is also often used in the setting of non-ccRCC, 
including in patients with advanced papillary RCC.
Because temsirolimus is generally used for metastatic 
RCC patients felt to be at high risk for a poor outcome, it 
is important to understand the criteria used to try and make 
that determination. Up until recently these patients have been 
stratified as having low-, intermediate-, or high-risk disease 
according to the so-called Motzer criteria.45 This system 
is based on a series of 5 potential high-risk features found 
to predict poor prognosis in patients with metastatic RCC 
treated with IFNα. These features include poor Karnofsky 
performance status, high lactate dehydrogenase, low serum 
hemoglobin, high corrected serum calcium, and time from 
RCC diagnosis to starting systemic therapy of less than 1 
year. Patients with no high-risk features are considered low-
risk, those with one or two features are intermediate-risk, 
and those with 3 or more features are considered high-risk. 
Studies are actively investigating how the advent of targeted 
newer therapies may have influenced or changed these cri-
teria.46 The temsirolimus trial used these criteria with the 
addition of one additional high-risk feature, ie, the presence 
of multiple organ metastases.
More recently, the oral mTOR inhibitor, everolimus, has 
also been tested in a large-scale, prospective, randomized, 
placebo-controlled Phase III trial in patients who had failed 
prior targeted therapies, including TKIs.47 Patients in the 
everolimus arm had better progression-free survival com-
pared with the placebo arm. As a consequence, everolimus 
is generally viewed as the standard second-line therapy in 
the setting of TKI failure.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Inhibitors of the VEGF pathway
Bevacizumab
Targeting the VEGF pathway has been accomplished   utilizing 
two distinct approaches. The most direct and   conceptually 
easiest way is to target the VEGF protein directly. A number 
of approaches have been explored to accomplish this, but 
the most advanced is the humanized monoclonal antibody 
to VEGF, bevacizumab (Avastin®, Genentech/Roche).48 
This novel intravenous agent was tested in a Phase III trial in 
combination with IFNα versus IFNα alone for men with pre-
viously untreated advanced RCC.49 The combination regimen 
demonstrated improved progression-free survival compared 
with the IFNα alone arm (10.2 months versus 5.4 months, 
respectively). As a consequence, bevacizumab in combination 
with IFNα is now approved for use in advanced RCC.
Tyrosine kinase inhibitors
A second approach to blocking the VEGF pathway is to inter-
rupt signaling from either the VEGF receptor or   signaling 
downstream from the receptor, rather than blocking the 
molecule itself. As alluded to earlier, the receptors for sev-
eral HIF targets, such as VEGF, PDGF, and TNFα are all 
tyrosine kinases. Furthermore, the downstream targets of 
these tyrosine kinase receptors are in turn often kinases in the 
RAF-MEK-ERK and the PI3-kinase-AKT-mTOR pathways. 
Molecules designed to target these kinases are referred to as 
TKIs. Early attempts to develop TKIs tended to focus on those 
agents which were relatively specific for the VEGF receptor 
itself.50,51 However, overall, the results were disappointing 
and the pursuit of these highly specific VEGFR agents has 
been largely abandoned. What has become apparent is that 
TKIs that are more “promiscuous”, ie, less specific and 
able to inhibit more than 1 kinase, seem to be more effec-
tive, presumably due to the inhibition of multiple pathways 
simultaneously. This concept has led to the development of 
several TKIs, including three currently approved for use in 
advanced RCC, ie, sunitinib, sorafenib, and the latest to be 
approved by the FDA, the second-generation TKI, pazopanib. 
In addition to these compounds, there is an ever-expanding 
list of potentially active agents in various stages of develop-
ment (eg, AG-013736, PTK787, and ZK222584). However, 
for this review, we will focus on the three approved for use 
in metastatic RCC, with particular emphasis on pazopanib 
(more in-depth reviews of the other agents have already been 
published).40,52,53
One of the first TKIs to be developed is the orally 
  bioavailable, multitargeted TKI sunitinib (Sutent®, Pfizer). 
Developmental and preclinical studies have shown that 
  sunitinib blocks the kinase activity of several important recep-
tors, including VEGFR and PDGFR.54,55 Promising Phase I56 
and Phase II57,58 studies in patients with advanced ccRCC 
led to a large-scale, prospective, randomized Phase III trial 
of 750 patients with advanced ccRCC who had not received 
prior systemic therapy (front-line setting).59 Patients in the 
sunitinib arm had a better median progression-free survival 
(11 months) compared with the IFNα arm (5 months). The 
objective partial response rate for the patients on sunitinib 
was 31% (compared with 6% for IFNα). Overall toxicity 
was manageable, with the most common Grade 3/4 adverse 
events being hypertension (8%), fatigue (7%), diarrhea (5%), 
hand–foot syndrome (5%), neutropenia (11%), lymphocy-
topenia (12%), and thrombocytopenia (8%). Sunitinib was 
approved for use on the basis of this study and has become 
the de facto standard front-line regimen for favorable-risk, 
advanced ccRCC.
A second, orally bioavailable, multitargeted TKI is 
sorafenib (Nexavar®, Onyx/Bayer). This was actually the 
first targeted therapy approved for use in advanced RCC in 
2005, and was originally developed as an inhibitor of Raf-1, 
a protein kinase in the Raf/MEK/ERK pathway which lies 
downstream of receptors such as VEGFR and PDGFR.60 
Later, it was found that sorafenib was also able to inhibit 
other tyrosine kinases, including VEGFR and PDGFR. The 
Phase II studies with sorafenib showed improvements in 
progression-free survival,23,61 which prompted a large-scale, 
multicenter, international, randomized, prospective trial of 
903 patients with advanced ccRCC who had failed 1 or more 
prior systemic therapies (second-line therapy).62 Patients were 
randomized to receive oral sorafenib or   placebo. Progression-
free survival was significantly better in the sorafenib arm, 
and therapy was generally well tolerated, although there 
were rare cases of significant hypertension and cardiac 
ischemia. It should be noted, that objective partial responses 
were generally uncommon with sorafenib. Sorafenib is 
now also approved for use in advanced ccRCC, although 
its use has generally been restricted to the second-line 
setting.
Pazopanib: a second-generation 
tyrosine kinase inhibitor
N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-
(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine 
(pazopanib) was initially discovered as part of a drug screen 
for agents that would potently inhibit VEGFR-2.38,39   However, Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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it has also been shown that, like the other   therapeutically 
  relevant TKIs, such as sunitinib and sorafenib, pazopanib can 
block the kinase activity of VEGFR-1, VEGFR-3, PDGFα, 
PDGFβ, as well as c-Kit.39,63,64 Pazopanib has been shown 
in vitro to inhibit the proliferation of human umbilical vein 
endothelial cells with an IC50 of 21 nM.39,64,65 Studies using 
a variety of in vivo human xenografts in mice have dem-
onstrated that pazopanib may have activity against a wide 
variety of malignancies, including prostate, colon, lung, 
melanoma, breast, as well as RCC.64 The optimum steady-
state concentration of pazopanib required to inhibit VEGFR-2 
in vivo is much higher than the IC50 of the in vitro studies, 
in the order of 40 µmol/L, which is thought to be due at 
least in part to the very high proportion of pazopanib which 
is protein-bound in vivo (over 99%).64,65 The elimination of 
pazopanib is thought to be mainly via metabolism through the 
cytochrome P450 system and in particular CYP3A4, although 
contributions are also made by CYP1A2 and CYP2C8.39,65,66 
On the basis of these promising preclinical studies, further 
clinical development of pazopanib was undertaken.
Clinical trial data for pazopanib
The first published Phase I trial of pazopanib was   initiated 
in patients with a variety of refractory solid tumors.67 
On the basis of the preclinical data, this trial was designed 
to achieve a steady-state pazopanib concentration of 
40 µmol/L.   Sixty-three patients were enrolled, with 43 in 
the dose-escalation phase of the study and 20 in the dose-
expansion phase. The oral dose of pazopanib was increased 
from 50 mg 3 times per week to 2000 mg once per day and 
300–400 mg twice per day. The most common toxicities were 
hypertension, diarrhea, hair depigmentation, and nausea, 
with hypertension being the most frequent Grade 3   toxicity. 
Dose-limiting toxicities were experienced at 800 mg and 
2000 mg daily, while steady-state exposure was noted at 
doses at or above 800 mg daily. The mean elimination half-
life of pazopanib was found to be 31.1 hours, and the mean 
target trough concentration was achieved at 800 mg once 
per day. In the group as a whole, 3 patients had an objec-
tive partial response and a further 14 had stable   disease for 
6 months or longer. Based on this study, 800 mg once per day 
was chosen as the dose to move forward for further clinical 
study. Of interest, 10 patients had refractory metastatic RCC, 
of which 4 achieved stable disease and one had an objec-
tive partial response.64 All of these patients showed some 
“clinical benefit”, and were treated with doses of 800 mg 
or higher, whereas the five who showed no obvious drug 
response were all treated with lower doses and did not reach 
the target trough concentration of .40 µM.
The encouraging results of this Phase I trial prompted a 
series of Phase II trials in patients with multiple solid tumors, 
but this review remains focused on a trial done for advanced 
ccRCC.68 This trial was originally designed as a randomized 
discontinuation study, similar to earlier Phase II studies of 
sorafenib,23,61 but was later changed to a more traditional 
open-label Phase II study based on the interim review by 
the study’s data safety monitoring committee after the first 
60 patients demonstrated a 38% objective/overall response 
rate at 12 weeks. In total, 225 patients were enrolled, of 
whom 69% were treatment-naive (front-line) while 31% 
had failed either cytokine therapy or a bevacizumab-based 
regimen. The objective/overall response rate was 35%, with 
a median progression-free survival of 1 year. The most 
common adverse events encountered were similar to those 
reported in the Phase I study, and included diarrhea, fatigue, 
hair depigmentation, and elevations of aspartate transaminase 
and alanine transaminase.
The promising results of this Phase II study in turn led 
to a large, prospective, randomized, double-blind, placebo-
controlled, international Phase III trial of pazopanib in 
patients with locally advanced or metastatic RCC.69 Histology 
had to be either pure or predominant ccRCC, consistent with 
the majority of Phase III trials with the other approved TKIs. 
The trial was originally designed to enroll patients who had 
failed prior cytokine therapy. However, due to the success 
of other TKIs, the population of cytokine-refractory patients 
rapidly became quite small, and the study was therefore 
amended to also include treatment-naïve patients. Patients 
were randomized 2:1 to pazopanib at 800 mg orally once 
daily or to placebo. Of the 435 patients enrolled, 233 (54%) 
were treatment-naïve. Patients randomized to pazopanib 
had a longer median progression-free survival compared 
with patients randomized to placebo (9.2 versus 4.2 months, 
respectively, hazard ratio [HR] 0.46, 95% confidence interval 
[CI] 0.34–0.62; P , 0.0001). This was also true in both the 
treatment-naïve (11.1 versus 2.8 months) and prior cytokine-
treated subgroups (7.4 versus 4.2 months). The overall objec-
tive response rate was 30%, with the vast majority being 
partial responses compared with 3% for patients on placebo 
(P , 0.001). Complete responses occurred in 1% of patients 
on pazopanib. The median duration of response was greater 
than one year. Toxicity was generally manageable, with the 
most common Grade 3/4 adverse events being diarrhea (3%), 
hypertension (4%), asthenia (3%), and alterations in alanine Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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transaminase (12%) or aspartate transaminase (7%).   Notably, 
Grade 3/4 hematologic adverse events were relatively 
uncommon. There was no meaningful difference in quality 
of life in the pazopanib-treated patients relative to placebo. 
On the basis of this trial, pazopanib was approved for use in 
advanced/metastatic RCC by the FDA in October 2009.
Pazopanib in context of other 
targeted therapies
The therapeutic landscape for ccRCC has changed dramati-
cally in the last 5 years. Less than a decade ago, the options 
were essentially two, ie, IFNα or high-dose IL-2. Neither 
was particularly satisfactory, and so the explosion of avail-
able options in many ways is a boon for both patients and 
their physicians. However, with this plethora of options 
come new questions and challenges. One of the first issues 
is the proper sequence and context in which the various new 
agents discussed in this review should be utilized. For the 
mTOR inhibitors, the Phase III data clearly support the use 
of temsirolimus as the first-line agent of choice for patients 
with intermediate- to high-risk metastatic disease. Similarly, 
the Phase III data for everolimus support its use in patients 
who have failed prior TKI therapy. Among the TKIs, however, 
the situation is not quite as clear.
In general, sorafenib is not typically used in the front-line 
setting and is usually utilized predominantly as a second-
line agent. However, for the lower-risk, treatment-naïve, 
or cytokine-refractory patient in whom sunitinib had been 
the de facto agent of choice, what now is the proper agent 
to use in this context? Should it be sunitinib or pazopanib? 
The efficacy data for these two agents in the largest Phase 
III trials to date are remarkably similar (see Table 1 for com-
parison of efficacy data). Both drugs were associated with 
a 30% objective overall response rate. The vast majority of 
these responses for both drugs were partial, with complete 
responses being relatively rare. Both agents appear to be asso-
ciated with a median progression-free survival of 11 months 
in the treatment-naïve population.
So how are we to decide? The key may be in the differ-
ing toxicity profiles of the two agents (see Table 2). In par-
ticular, the rash and hand–foot syndrome that is often seen 
with sunitinib is quite rare with pazopanib. Pazopanib also 
appears to induce less neutropenia and lymphocytopenia than 
sunitinib, although this may be offset by a higher incidence 
of hypertension and abnormalities of aspartate transaminase 
and/or alanine transaminase (see Table 2). Interestingly, some 
work has suggested that the reduced myelosuppression with 
pazopanib may be due to differences in the kinase selectiv-
ity of this agent versus other TKIs, in particular less activity 
against Flt-3.63 Therefore, it may be that the choice of agents 
is determined to some degree by a patient’s comorbidities or 
tolerance of one agent over the other. Clearly, choosing the 
best therapy would be best tested in the context of a random-
ized trial. Fortunately, in the case of comparing sunitinib with 
pazopanib in the front-line setting, just such a trial is planned 
and ongoing (NCT00720941 at clinicaltrials.gov).39,69 The 
results of this trial are eagerly anticipated and should shed 
some light on the relative benefits and risks of these agents. 
Table 1 Comparison of efficacy data across targeted agents in phase III randomized trials*
Agent Setting Pts (n) OR % PR % CR % PFS (mo) OS (mo)
Pazopanib69 Front-line (54%)  290 30 30 ,1 9.2 –
Placebo Cytokine failure (46%) 145 3 3 0 4.2 –
Sunitinib59 Front-line 375 31 31 0 11 26.471
IFNα 375 6 6 0 5 21.8
Sorafenib62 Cytokine failure 451 10 10 ,1 5.5 17.872
Placebo 452 2 2 0 2.8 15.2
Bevacizumab49 and IFNα Front-line 327 31 30 2 10.2 –
IFNα 322 13 11 1 5.4 –
Temsirolimus44 Front-line  209 8.1 – – 3.8 10.9
Temsirolimus and IFNα Poor prognosis 210 8.6 – – 3.7 8.4
IFNα 207 4.8 – – 1.9 7.3
Everolimus47 TKI failure 272 1 1 0 4.0 –
Placebo 138 0 0 0 1.9 –
*Note that none of these trials compared these targeted agents directly against one another in a head to head fashion; if only the comparator arm was reported and not the 
intervention arm, neither is included. Note also that for sunitinib and sorafenib, follow-up studies were used instead of the original Phase III trial report.
Abbreviations: OR, objective response rate (partial response plus complete response where both investigator and independent review results were reported, the 
independent review is presented); PR, objective partial response rate; CR, objective complete response rate; PFS, median progression-free survival; OS, median overall 
survival; TKI, tyrosine kinase inhibitor; IFNα, interferon-alpha; pts, patients, n, number; mo, months. Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 2 Comparison of toxicity in phase III studies of sunitinib and pazopanib59,69,*
Parameter Pazopanib (n = 290) Sunitinib (n = 375)
Any (%) Grade 3 (%) Grade 4 (%) Any (%) Grade 3 (%) Grade 4 (%)
Diarrhea 52 3 ,1 53 5 0
Hypertension 40 4 0 24 8 0
Hair color changes 38 ,1 0 14 0 0
Nausea 26 ,1 0 44 3 0
Anorexia 22 2 0 ,10 0 0
Vomiting 21 2 1 24 4 0
Fatigue 19 2 0 51 7 0
Asthenia 14 3 0 17 4 0
Abdominal pain 11 2 0 ,10 0 0
Headache 10 0 0 11 1 0
Stomatitis ,10 0 0 25 1 0
Hand-foot syndrome ,10 0 0 20 5 0
Mucosal Inflammation ,10 0 0 20 2 0
Rash ,10 0 0 19 1 1
Dry skin ,10 0 0 16 1 0
Skin discoloration ,10 0 0 16 0 0
Epistaxis ,10 0 0 12 1 0
Pain in limb ,10 0 0 11 1 0
Dry mouth ,10 0 0 11 0 0
Decline in EF ,10 0 0 10 2 0
ALT Increase 53 10 2 46 2 1
AST Increase 53 7 ,1 52 2 0
Hyperglycemia 41 ,1 0 ,10 0 0
Total bilirubin increase 36 3 ,1 19 1 0
Hypophosphatemia 34 4 0 36 4 1
Hypocalcemia 33 1 1 ,10 0 0
Hyponatremia 31 4 1 ,10 0 0
Hypomagnesemia 11 3 0 ,10 0 0
Hypoglycemia 17 0 ,1 ,10 0 0
Leukopenia 37 0 0 78 5 0
Neutropenia 34 1 ,1 72 11 1
Thrombocytopenia 32 ,1 ,1 65 8 0
Lymphocytopenia 31 4 ,1 60 12 0
Anemia ,10 0 0 71 3 1
Increased creatinine ,10 0 0 66 1 0
Increased lipase ,10 0 0 52 13 3
Increased ALP ,10 0 0 42 2 0
Increased uric acid ,10 0 0 41 0 12
Increased amylase ,10 0 0 32 4 1
*Note these were not compared head-to-head in these trials, therefore no P value given.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; EF, ejection fraction.
As more targeted therapeutics come online, the challenge will 
be to do the trials to place each of these in their proper place 
within the armamentarium for advanced RCC. Another TKI, 
axitinib (AG013736, Pfizer), is also undergoing active testing 
in Phase III trials in RCC (NCT00678392 and NCT00920816 
at clinicaltrials.gov) although as of the time of writing these 
trials are both still accruing patients.
Another question that remains unanswered at this point 
concerns combination therapy. To this point, the targeted 
  therapies have completed testing in combination only with 
IFNα. For example, bevacizumab was tested in combination 
with IFNα versus IFNα alone, with the combination shown to 
be superior.49 On the other hand, in the case of temsirolimus, the 
combination with IFNα was in fact inferior to   monotherapy.44 
To date, whether disparate targeted agents can be used reliably 
in combination regimens remains unclear and should only 
be undertaken in the context of a clinical trial. However, there 
are some intriguing data suggesting that pazopanib may have 
synergistic activity when combined with agents targeted to 
other kinases, such as HER1 and HER2. In an in vitro study Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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predominantly in non-small-cell lung cancer, the combination 
of pazopanib and lapatinib synergistically inhibited the growth 
of cancer cells and had activity against other kinases (such as 
c-Met) that ordinarily are only weak targets of these agents 
when used alone.70 Based on such preclinical studies, a Phase 
II study of this combination has been completed for advanced/
metastatic breast cancer with promising results and another is 
underway for metastatic cervical cancer.39
Another open question in the management of metastatic 
RCC concerns the most appropriate therapy for patients with 
non-clear cell histology. The default strategy at present is to 
treat these patients with temsirolimus, based on its activity 
in the previously discussed Phase III trial.44 However, true 
progress in managing patients with non-ccRCC will likely 
depend on a better understanding of the biology of this dis-
tinct disease entity, and developing agents that are targeted 
to its pathobiology. Pertinent to pazopanib is again research 
demonstrating its activity against c-Met when combined with 
lapatinib, a HER1/HER2 kinase inhibitor.70 Since a subtype 
of papillary RCC (Type 1) is thought to be predominantly 
associated with aberrations in c-Met, this raises the intrigu-
ing possibility that the combination regimen of pazopanib-
lapatinib may be useful for this disease. Clearly such a 
hypothesis must be tested in a properly executed clinical trial, 
but this highlights the potential of combination therapy that 
is rationally designed and implemented. It also points to the 
critical role that preclinical studies will play in prioritizing 
which agents to combine and the diseases in which to test 
these combinations.
Conclusion
ccRCC has a distinct tumor biology which hinges on aber-
rations of the VHL protein and the accumulation of HIFα in 
the tumor cell. Therapies targeted to this biology, including 
the TKIs, have dramatically improved the management of 
advanced and metastatic ccRCC. Among these, pazopanib 
is the latest oral, multikinase TKI to be approved for use in 
advanced RCC. The precise role for pazopanib relative to the 
other targeted agents remains to be fully elucidated, but it is 
likely to compete directly with sunitinib in the front-line setting 
for lower-risk metastatic disease. A head-to-head trial should 
shed further light on this important issue. Future trials will also 
need to address the potential utility of   combination therapy and 
explore ways of treating non-ccRCC more effectively.
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